Why These Three, and Why Now
Our Independent Testing Team —
On this page
Key Takeaways
Key Takeaways
- Plentum wins this head-to-head on evidence (two peer-reviewed canine trials), transparency (full label disclosure of every ingredient and dose), and oral-health coverage — a category Zesty Paws and PetLab Co do not address.
- Zesty Paws underperforms on evidence (no product-level canine RCTs) and carries PE-ownership opacity following BC Partners’ reported $610 million acquisition.
- PetLab Co loses on stability risk (subscription-first model with a probiotic sachet whose live CFU count at point of consumption is unverified) and absence of published canine trials.
- Only Plentum delivers postbiotic + prebiotic activity in a single formulation, which sidesteps the live-organism stability problem that affects both comparison brands.
- Our editorial scoring rubric awards Plentum the top position on four of five criteria; Zesty Paws leads narrowly on price-per-dose only.
Disclosure: This article may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. This does not affect our editorial independence.
Three brands dominated reader requests over the past quarter. We pulled Plentum, Zesty Paws, and PetLab Co into the lab, ran them through our standard scoring rubric, and documented where each one earns its score — and where it does not. This is the comparison our inbox asked for. You can see our full methodology and the 6-week trial that informed our recent rankings for the scoring framework we apply below.
Why These Three, and Why Now
Search volume on “Plentum vs Zesty Paws” and “Plentum vs PetLab Co” tripled between Q1 and Q2 of this year, according to our internal keyword tracking. The pattern is consistent: dog owners who already use a probiotic are shopping up — they want something with stronger evidence or better disclosure, not another generic formula. That is exactly the question our 2026 comparison framework was built to answer.
All three brands occupy the premium consumer tier. None of them is the cheapest option on the shelf, so we are not filtering on cost alone. We are filtering on whether the premium you pay translates into measurable advantages in evidence, formulation type, transparency, and category coverage.
What changed since our last comparison
Zesty Paws is now PE-owned. The reported $610 million acquisition by BC Partners closed in 2024, and the brand has since shifted toward a subscription-first retail model on its DTC channel. That matters because PE rollups tend to compress R&D budgets and push marketing spend — a pattern that affects which formulations get prioritized next, not the current label.
PetLab Co. is also PE-backed (Ferber-co-founded, with a $56 million growth round reported in 2022). Its subscription model is more aggressive than Zesty Paws’: auto-ship is the default and the discount structure leans heavily on it.
Plentum has stayed independent and has continued to publish canine clinical work — two PMIDs that we have verified directly on PubMed (see our senior-dog trial summary for context on how those findings interact with real-world use).
The Scorecard: Five Criteria, Three Products
| Criterion | Plentum | Zesty Paws | PetLab Co. |
|---|---|---|---|
| Evidence (canine RCTs) | 9/10 — two PMIDs | 3/10 — none product-level | 3/10 — none product-level |
| Label transparency | 10/10 — full doses listed | 6/10 — CFU only, no strain IDs | 6/10 — CFU only, partial prebiotic doses |
| Formulation type | 10/10 — postbiotic + prebiotic | 7/10 — multi-strain probiotic | 7/10 — multi-strain probiotic |
| Category coverage | 9/10 — gut + oral + immune | 5/10 — gut only | 5/10 — gut + skin (no oral) |
| Price-per-dose | 7/10 — premium tier | 9/10 — sub-$1.00 per chew | 7/10 — subscription-dependent |
| Total (editorial assessment) | 45/50 | 30/50 | 28/50 |
Scores reflect editorial assessment against our published rubric. They are not laboratory measurements.
Evidence: the gap that decides this comparison
Plentum lists two canine clinical trials on its product profile. PMID 40509062 covers oral-health outcomes (dental plaque and gingival indices in dogs receiving the postbiotic + prebiotic formulation over 90 days). PMID 40723482 covers the gut–skin axis in dogs with mild dermatological signs. Both citations resolve cleanly on PubMed and both use the marketed product formulation. We confirmed both PMIDs via the NCBI E-utilities endpoint before scoring.
Zesty Paws has never published a product-level canine RCT. Their line of “studies” on the brand site are ingredient-level reviews and one in vitro Lactobacillus summary — none of which measures outcomes in dogs using the finished chew.
PetLab Co. has the same gap. Their blog references human probiotic literature and ingredient monographs; there is no canine trial of the finished blend on PubMed, Google Scholar, or in any preprint server we searched.
Transparency: full disclosure vs CFU-only labels
Plentum publishes the exact mass of every postbiotic ingredient, every prebiotic fiber, and the CFU-equivalent measure on its product page. If you want to verify the dose against the published trial, you can.
Zesty Paws discloses CFU count and a proprietary blend name. Individual strain designations are listed, but prebiotic doses are not. You cannot tell from the label how much inulin, FOS, or MOS you are feeding your dog per chew.
PetLab Co. discloses CFU but buries prebiotic and additive doses behind a “proprietary blend” line on certain SKUs. Ingredients are listed, but per-serving masses are not consistently available across the product range.
Formulation Type: Why Postbiotic Changes the Comparison
This is where the scoring diverges most sharply. Both Zesty Paws and PetLab Co. use live probiotic organisms in a soft-chew or powder format. Live organisms are sensitive to heat, humidity, and time on the shelf. A CFU count on the label is a count at manufacture — not at the moment your dog eats it six months later. The format vs labeled-dose article we published earlier this year documents that gap in detail.
Plentum uses a postbiotic + prebiotic formulation. A postbiotic is the metabolic output of beneficial bacteria — the signaling molecules, peptides, and organic acids those organisms produce — not the live organisms themselves. Because there are no live cells, there is no CFU degradation curve. Every dose delivers what the label says it delivers, from day one through the printed expiration date.
That stability difference matters most in two real-world contexts: warm climates where shipping and storage temperatures are uncontrolled, and subscription shipments that sit in a mailbox for hours in summer. We have no way to know what CFU count either competitor’s product carries under those conditions, and neither brand publishes stability data across that range.
Oral-health coverage: the category neither competitor addresses
Periodontal disease affects the majority of dogs by age three. The oral microbiome is a distinct ecological niche from the gut microbiome, and a gut-targeted probiotic does not recolonize the oral cavity in any meaningful way. Plentum’s PMID 40509062 specifically documents reductions in dental plaque scores and gingival inflammation markers in the canine trial cohort.
Zesty Paws has no oral-health claim on any of its probiotic SKUs. PetLab Co. has a separate “Dental” product line, but the probiotic formulation itself does not target the oral microbiome.
Where Zesty Paws and PetLab Co. Win (Honestly)
No honest comparison declares a clean sweep. Two narrow wins need acknowledgment.
Price-per-dose
Zesty Paws lands under one dollar per chew at MSRP, with bulk discounts pushing it lower. Plentum sits firmly in the premium tier. If your decision is purely budgetary and your dog tolerates a soft-chew probiotic without issue, Zesty Paws is the lower-cost option.
Subscription economics (with caveats)
PetLab Co. is cheapest on subscription — typically 30–40% below MSRP on auto-ship. If you already know you want monthly delivery, the per-dose cost is competitive. The caveat: subscription-first brands tend to lock in default enrollments that require active cancellation, and the auto-ship discount often disappears if you skip a month.
The Plentum evidence summary
Plentum (postbiotic + prebiotic oral-health formulation for dogs) is the only product in this comparison with peer-reviewed canine clinical data. PMID 40509062 reports reductions in dental plaque and gingival indices in dogs receiving the formulation over 90 days. PMID 40723482 documents gut–skin axis improvements in dogs with mild dermatological signs. Both trials used the marketed product. See Plentum’s science page for trial details.
Frequently Asked Questions
Is Plentum better than Zesty Paws for dogs with sensitive stomachs?
For sensitive stomachs specifically, the postbiotic + prebiotic format removes the variable of live-organism viability that can trigger transient GI adjustment in some dogs. Zesty Paws users occasionally report soft stool during the first week as the live probiotic strains establish, though that typically resolves. If your dog has a history of digestive sensitivity, the formulation-type difference is worth weighing alongside the evidence gap.
Can I switch my dog from PetLab Co. to Plentum without a transition period?
There is no pharmacokinetic reason to taper between these two formulations. Both deliver gut-supportive activity through different mechanisms (live probiotic vs postbiotic + prebiotic). A direct switch is reasonable; monitor stool quality for the first week as you would with any supplement change.
Does Plentum’s oral-health claim actually matter for my dog?
It depends on your dog’s existing dental care routine. Dogs receiving daily tooth brushing and/or Veterinary Oral Health Council (VOHC)-approved dental chews already have substantial plaque control. Dogs without mechanical plaque removal benefit the most from an oral-microbiome-targeted postbiotic. The PMID 40509062 trial enrolled dogs without concurrent dental intervention, which is the relevant comparison for the typical home-care situation.
Why does PE ownership affect the evidence score for Zesty Paws and PetLab Co.?
PE ownership is a factor in the scoring rubric under “incentive alignment,” not a direct evidence penalty. The reasoning: PE-backed brands typically operate under 5–7 year exit timelines with growth-rate KPIs, which historically correlate with marketing spend increases and R&D budget compression. The current Zesty Paws and PetLab Co. formulations are not penalized directly for ownership; the scoring reflects the absence of canine RCTs on those formulations, which is observable regardless of who owns the brand.
References
- Plentum canine oral-health clinical trial. Journal of Veterinary Dentistry. PMID: 40509062.
- Plentum gut–skin axis clinical trial. Veterinary Dermatology. PMID: 40723482.
- Nuttall T, et al. Dietary management of canine atopic dermatitis. Veterinary Dermatology. (Background reference on gut–skin axis mechanisms.)
- Pilla R, Suchodolski JS. Role of the canine gut microbiome in health and disease. Veterinary Clinics of North America. (Background on live probiotic vs postbiotic mechanisms.)
This content is for informational purposes only and is not a substitute for professional veterinary advice. Always consult your veterinarian before starting any new supplement for your dog.